PDCD1 and gastric cancer: A more convincing, although not conclusive, predictive role for PD-L1 expression, as measured by the combined positive score (CPS), has become increasingly evident in clinical trials investigating immunotherapy in the first or subsequent lines of treatment in GC, as an increasing CPS has been associated with improved outcomes with PD-1 inhibitors.